|Articles|May 1, 2004

The switch to ASP in 2005: What you need to know

Here's some important advice for urologists while we await final detailson new payment system

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

From hype to practice: Urologists assess AI's real impact

ByHannah Clarke

July 30th 2026

The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD

ByAdam B. Weiner, MD,Jason Hafron, MD

July 24th 2026

University of Florida chief residents discuss mentorship, self-care, and residency success

ByMiranda Eubank, MD,Trisha U. Nguyen, MD,Jordan Matthews-Smith, MD

July 15th 2026

The UroOnc Minute: Making Appointments More Effective, With David Canes, MD

ByAdam B. Weiner, MD,David Canes, MD

July 3rd 2026

Money Matters: How can you plan for your retirement income needs?

ByRonald J. Paprocki, JD, CFP, CHBC

May 29th 2026

Latest CME

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

The switch to ASP in 2005: What you need to know

Related Content

From hype to practice: Urologists assess AI's real impact

The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD

University of Florida chief residents discuss mentorship, self-care, and residency success

The UroOnc Minute: Making Appointments More Effective, With David Canes, MD

Money Matters: How can you plan for your retirement income needs?

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Radioligand Therapy 101: The Science Behind the Strategy

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Individualizing androgen pathway therapy in mCSPC

Testosterone deficiency: FAQs from the AUA guideline

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

Cretostimogene Grenadenorepvec: Mechanism and Rationale